Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23546202 | 0.87 | NR1H2 (0.43) | CHRM2CHRM1CHRM3ATMHSD17B10 | |
| SCHEMBL16043709 | 0.87 | NR1H2 (0.40) | CHRM2CHRM1CHRM3DPP4NR1H2 | |
| SCHEMBL28731364 | 0.87 | NR1H2 (0.40) | CHRM2CHRM1CHRM3DPP4NR1H2 | |
| SCHEMBL15056773 | 0.87 | NR1H2 (0.40) | CHRM2CHRM1CHRM3DPP4NR1H2 | |
| SCHEMBL29163844 | 0.87 | NR1H2 (0.40) | CHRM2CHRM1CHRM3DPP4NR1H2 | |
| SCHEMBL15057262 | 0.87 | NR1H2 (0.40) | CHRM2CHRM1CHRM3DPP4NR1H2 | |
| SCHEMBL1630475 | 0.86 | HTT (0.43) | CHRM2CHRM1CHRM3ATMHSD17B10 | |
| SCHEMBL1398690 | 0.86 | HTT (0.43) | CHRM2CHRM1CHRM3ATMHSD17B10 | |
| SCHEMBL1630474 | 0.86 | HTT (0.43) | CHRM2CHRM1CHRM3ATMHSD17B10 | |
| SCHEMBL297706 | 0.85 | CHRM2 (0.39) | CHRM2CHRM1CHRM3ATMDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | CHRM2 4879/4885CHRM1 4868/4885CHRM3 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.